D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
RVNC holding history
Revance Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
RVNC overviewAll 13F holders of RVNCFull Q2 2026 holdings
- Shares (Q1 2025)
- 0
- Sold out in Q1 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 15
- Since Q2 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2025 | 0 | $0 | 0.0% | −1,367,343−100.0% | Sold out | Holders |
| Q4 2024 | 1,367,343 | $4.16M | <0.1% | −564,862−29.2% | Reduced | Holders |
| Q3 2024 | 1,932,205 | $10.0M | <0.1% | +1,824,225+1,689.4% | Added | Holders |
| Q2 2024 | 107,980 | $277.5K | <0.1% | −190,130−63.8% | Reduced | Holders |
| Q1 2024 | 298,110 | $1.47M | <0.1% | −113,640−27.6% | Reduced | Holders |
| Q4 2023 | 411,750 | $3.62M | <0.1% | −370,266−47.3% | Reduced | Holders |
| Q3 2023 | 782,016 | $8.97M | <0.1% | −1,229,653−61.1% | Reduced | Holders |
| Q2 2023 | 2,011,669 | $50.9M | 0.1% | −280,242−12.2% | Reduced | Holders |
| Q1 2023 | 2,291,911 | $73.8M | 0.1% | +952,991+71.2% | Added | Holders |
| Q4 2022 | 1,338,920 | $24.7M | <0.1% | −130,653−8.9% | Reduced | Holders |
| Q3 2022 | 1,469,573 | $39.7M | 0.1% | +651,833+79.7% | Added | Holders |
| Q2 2022 | 817,740 | $11.3M | <0.1% | −28,528−3.4% | Reduced | Holders |
| Q1 2022 | 846,268 | $16.5M | <0.1% | +322,350+61.5% | Added | Holders |
| Q4 2021 | 523,918 | $8.55M | <0.1% | +514,678+5,570.1% | Added | Holders |
| Q3 2021 | 9,240 | $257.0K | <0.1% | −38,847−80.8% | Reduced | Holders |
| Q2 2021 | 48,087 | $1.43M | <0.1% | +48,087 | New | Holders |